Parvovirus B19 Infection in Pregnancy Studied by Maternal Viral Load and Immune Responses

2006 ◽  
Vol 22 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Timo R. de Haan ◽  
Matthias F.C. Beersma ◽  
Eric C.J. Claas ◽  
Dick Oepkes ◽  
Aloys C.M. Kroes ◽  
...  
Keyword(s):  
Viral Load ◽  
Immune Responses ◽  
Parvovirus B19 ◽  
Maternal Viral Load ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Parvovirus B19 infection in pregnancy: maternal and fetal viral load measurements related to clinical parameters

2006 ◽  
Vol 27 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Timo R. de Haan ◽  
Matthijs F. C. Beersma ◽  
Dick Oepkes ◽  
Eveline P. de Jong ◽  
Aloys C. M. Kroes ◽  
...  
Keyword(s):  
Viral Load ◽  
Parvovirus B19 ◽  
Clinical Parameters ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Parvovirus B19 Infection in Pregnancy: Maternal and Fetal Viral Load Measurements Related to Clinical Parameters

2007 ◽  
Vol 62 (4) ◽  
pp. 230-231
Author(s):  
Timo R. de Haan ◽  
Matthijs F. C. Beersma ◽  
Dick Oepkes ◽  
Eveline P. de Jong ◽  
Aloys C. M. Kroes ◽  
...  
Keyword(s):  
Viral Load ◽  
Parvovirus B19 ◽  
Clinical Parameters ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases

2004 ◽  
Vol 24 (7) ◽  
pp. 513-518 ◽  
Author(s):  
Martin Enders ◽  
Andrea Weidner ◽  
Iris Zoellner ◽  
Karen Searle ◽  
Gisela Enders
Keyword(s):  
Parvovirus B19 ◽  
Morbidity And Mortality ◽  
Human Parvovirus B19 ◽  
Prospective Evaluation ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Diagnosis, management and possibilities to prevent parvovirus B19 infection in pregnancy

2011 ◽  
Vol 6 (12) ◽  
pp. 1435-1450 ◽  
Author(s):  
Annelie Plentz ◽  
Susanne Modrow
Keyword(s):  
Parvovirus B19 ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Parvovirus B19 infection in pregnancy — awareness and opportunities

2017 ◽  
Vol 27 ◽  
pp. 8-14 ◽  
Author(s):  
Francesca Bonvicini ◽  
Gloria Bua ◽  
Giorgio Gallinella
Keyword(s):  
Parvovirus B19 ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Case 39

2020 ◽  
pp. 269-276
Author(s):  
Katie Jeffery
Keyword(s):  
Viral Infection ◽  
Viral Infections ◽  
Parvovirus B19 ◽  
Adverse Outcomes ◽  
Varicella Zoster ◽  
Parvovirus B19 Infection ◽  
Diagnostic Approaches ◽  
In Pregnancy

Viral infection in pregnancy can lead to adverse outcomes for both the mother and the foetus. This chapter examines the steps to be taken on exposure to viruses associated with rash illness in pregnancy. Consideration is given to the important points in the history, which viral infections are of concern in pregnancy (varicella-zoster, parvovirus B19, rubella, measles, and Zika), the possible outcomes of infection, diagnostic approaches, and the management of a confirmed case of Parvovirus B19 infection.

scholarly journals Congenital Parvovirus B19 Infection: Persistent Viremia and Red Blood Cell Aplasia

2015 ◽  
Vol 2 (2) ◽  
Author(s):  
Sruti S. Nadimpalli ◽  
Russell S. Miller ◽  
Vasudeva M. Kamath ◽  
Christiana R. Farkouh ◽  
Chia-Ling Nhan-Chang ◽  
...  
Keyword(s):  
Viral Load ◽  
Preterm Birth ◽  
Blood Cell ◽  
Parvovirus B19 ◽  
Immunoglobulin Therapy ◽  
Intravenous Immunoglobulin Therapy ◽  
Serum Viral Load ◽  
Persistent Viremia ◽  
Parvovirus B19 Infection ◽  
Immunoglobulin Treatment

Abstract We describe a case of fetal parvovirus B19 infection resulting in preterm birth and leading to hydrops fetalis requiring multiple in utero transfusions. The infant developed chronic postnatal anemia responsive to intravenous immunoglobulin therapy. Serum viral load decreased after immunoglobulin treatment but remained detectable for over 1 year.

Six cases of parvovirus B19 infection in pregnancy

2016 ◽  
Vol 118 ◽  
pp. 120
Author(s):  
Saki Sato ◽  
Mayumi Morizane ◽  
Daisuke Ueda ◽  
Yoko Maesawa ◽  
Shinya Tairaku ◽  
...  
Keyword(s):  
Parvovirus B19 ◽  
Parvovirus B19 Infection ◽  
In Pregnancy

Changes in erythron peripheral component during chemotherapy in patients with malignant lymphomas and parvovirus B19 infection.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20086-e20086
Author(s):  
Nailya K. Guskova ◽  
Tatiana A. Zykova ◽  
Irina B. Lysenko ◽  
Ekaterina A. Guskova ◽  
Anastasia S. Nozdricheva ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Viral Load ◽  
Parvovirus B19 ◽  
Microcytic Anemia ◽  
Malignant Lymphomas ◽  
Hypochromic Microcytic Anemia ◽  
Before And After ◽  
Parvovirus B19 Infection ◽  
Expected Increase ◽  
Timely Treatment

e20086 Background: The purpose of the study was to analyze changes in the erythron peripheral component during chemotherapy for malignant lymphomas in patients infected with parvovirus B19 (B19V). Methods: The study included 34 patients with lymphomas (48.7±4.3 years). B19V infection was determined by the presence of IgM/IgG antibodies to B19V in blood serum and DNA in blood plasma and bone marrow before chemotherapy (CT). Parameters of the erythron peripheral component - RBC, HGB, MCW, MCH, MCHC, RDW, PLT, RET (#), IRF, LFR, MFR, HFR (%), and myelogram were evaluated before and after CT (Sysmex XE 2100, Japan). Results: 82.5% of patients had IgG to B19V, including IgM in 11.8%. B19V DNA was detected in 23.4% of patients: in the bone marrow and blood in 11.7%, only in the bone marrow in 11.7%. The range of viral load in the bone marrow was 1435-79573 IU/ml, in the blood 2-349 IU/ml. RBC in all patients before CT was within the reference range, with a tendency to decrease in the group with B19V: 4.01±0.06×1012/L with B19V and 4.57±0.08×1012/L without B19V. Levels of HGB before CT were respectively 112±1.26 g/L and 116±1.26 g/L, decreasing after CT by 1.5 and 1.3 times (p < 0.05) depending on the viral load. MCV, MCH and MCHC varied: 78.6 – 84.8 fl, 24.9 – 28.0 pg and 314–330 g/L in the group with B19V, and 89.7–91.3 fl, 29.5–29.8 pg and 324–337 g/L, respectively, in the group without B19V, which indicates the development of hypochromic microcytic anemia. RET levels before CT in the group with B19V were 38.3±3.44×109/L, after CT – 10.6±2.7×109/L, being lower than in the group without B19V by 1.8 and 3.8 times (p < 0.001), respectively. IRF, MFR and HFR in patients with B19V before CT were 10.6±2.23%, 9.5±1.54% and 1.1±0.022%, being lower than in non-infected patients by 1.6, 1.3 and 3.6 times, respectively. After CT, the downward trend in the proportion of young fractions continued. The noted changes in the erythron peripheral unit indicated inhibition of erythropoiesis, more pronounced in patients with B19V, and were consistent with the myelogram data. Conclusions: The development of anemia without the expected increase in RET, and in particular immature forms - IRF, MFR, HFR - in patients with lymphomas and B19V infection indicates inhibition of erythropoiesis. Early manifestation of these changes allows for timely treatment correction.

Sign in / Sign up

Export Citation Format

Share Document